HSA & FSA eligible

Semaglutide Cuts Cardiovascular Events in Landmark Trial

Human hand with weight loss pills and bottle with blur yoga mat on the floor in the background

Mitchel L. Zoler, PhD August 08, 2023 The popular but expensive weight-loss drug, semaglutide (Wegovy), significantly reduced major adverse cardiovascular events (MACE) by 20% when given to patients, compared with those receiving placebo, in the pivotal SELECT trial, with more than 17,000 enrolled people with overweight or obesity and established cardiovascular disease (CVD), but no diabetes. The…